Choate Investment Advisors Acquires 37 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Choate Investment Advisors grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.2% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 551 shares of the biopharmaceutical company’s stock after purchasing an additional 37 shares during the quarter. Choate Investment Advisors’ holdings in Regeneron Pharmaceuticals were worth $392,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of REGN. FSA Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $26,000. OFI Invest Asset Management bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $28,000. Rakuten Securities Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 15 shares in the last quarter. Private Wealth Management Group LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 39 shares in the last quarter. Finally, Truvestments Capital LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $39,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $678.42 on Tuesday. The stock has a market cap of $74.17 billion, a price-to-earnings ratio of 17.72, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20. The stock’s 50-day moving average is $694.15 and its 200 day moving average is $827.65.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm earned $11.86 EPS. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.52%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Piper Sandler cut their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a report on Monday, January 27th. Canaccord Genuity Group cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Sanford C. Bernstein cut their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Finally, Wells Fargo & Company lowered their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.